Abstract 【Objective】 To investigate the clinical efficacy of different antiplatelet drug therapy in clopidogrel resistant patients with acute coronary syndrome (ACS).【Methods】 From July 2015 to June 2017, 220 ACS patients with clopidogrel resistance were selected. All patients received percutaneous coronary intervention (PCI). They were randomly divided into observation group and control group with 110 cases in each group. The control group was treated with clopidogrel + aspirin + cilostazol and the observation group with tigrilol + aspirin. The clinical efficacy and safety of the two treatments were compared.【Results】 There was no significant difference in platelet inhibition rate induced by adenosine diphosphate (ADP), arachidonic acid (AA) between the two groups (all P>0.05). The platelet inhibition rate of the ADP pathway in the observation group was significantly lower than that in the control group at 1 and 6 months postoperatively (P<0.05). The incidence of cardiovascular death, myocardial infarction and recurrent angina pectoris in the observation group was lower than that in the control group, and the incidence of thrombus in stent was higher than that in the control group, but there was no significant difference between the two groups (P>0.05). There was no significant difference between the two groups in the occurrence of severe bleeding, slight hemorrhage, rash, gastrointestinal reaction, thrombocytopenia and dyspnea (P>0.05).【Conclusion】 The therapy of ACS patients with clopidogrel resistance by aspirin, cilostazol and clopidogrel, or tigrilol as a replacement of clopidogrel has good clinical efficacy and good safety.
HONG Wei-jie,SHI Jun-ting. Comparison of Two Antiplatelet Regimens in the Treatment of Clopidogrel Resistant Acute Coronary Syndrome[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(9): 1683-1685.
2018, Vol. 35 
